AT7519 trifluoroacetate is primarily used in research settings as a potent and selective inhibitor of cyclin-dependent kinases (CDKs). It plays a significant role in studying cell cycle regulation and apoptosis, particularly in cancer research. By inhibiting CDKs, it helps researchers understand the mechanisms of tumor growth and proliferation, making it a valuable tool in the development of targeted cancer therapies. Additionally, it is utilized in preclinical studies to evaluate its efficacy in inhibiting the growth of various cancer cell lines, providing insights into potential therapeutic applications. Its application extends to exploring the effects of CDK inhibition on cellular processes, aiding in the identification of novel drug targets for treating malignancies.